电邮这篇文章 Reserpine Is the New Addition into the Repertoire of AcrB Efflux Pump Inhibitors
- 作者: Shaheen A.1,2, Afridi W.A.1, Mahboob S.1, Sana M.1, Zeeshan N.2, Ismat F.1, Mirza O.3, Iqbal M.1, Rahman M.1
-
隶属关系:
- Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE)
- Department of Biochemistry and Biotechnology, University of Gujrat, Hafiz Hayat Campus
- Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen
- 期: 卷 53, 编号 4 (2019)
- 页面: 596-605
- 栏目: Structural-Functional Analysis of Biopolymers and Their Complexes
- URL: https://journal-vniispk.ru/0026-8933/article/view/164029
- DOI: https://doi.org/10.1134/S0026893319040113
- ID: 164029
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
订阅存取
详细
Acriflavine resistance protein B (AcrB) serves as prototype for multidrug resistance (MDR) efflux transporters of resistance nodulation division (RND) superfamily. AcrB has been proven as potential drug target with many synthetic and natural inhibitors have been identified such as those belonging to pyranopyridine, naphthamide and pimozide classes. The plant derived alkaloid inhibitors represented by reserpine has been found to inhibit both ATP binding cassette and major facilitator efflux transporters. In this study we report the reserpine induced inhibition of RND transporter AcrB. The preliminary docking analysis hints that reserpine shares its binding site with ciprofloxacin, a known substrate of AcrB and could possibly act as competitive inhibitor. For in vitro validation, AcrB from Salmonellatyphi was cloned under the control of tac promoter and resulting vector was introduced into E. coli C41(DE3). Under autoinduced conditions, cells overexpressing AcrB transporter were subjected to combined dose of ciprofloxacin and reserpine. The combined exposure resulted in enhanced ciprofloxacin-induced growth inhibition of cells expressing AcrB transporter as compared to control cells transformed with vector of backbone sequence. Time kill analysis further confirmed these findings. To the best of our knowledge, this is first study to show that exposure to reserpine induces inhibition of AcrB. The assay developed in this study allows simple and reproducible detection of substrate/inhibitor effects upon AcrB and related efflux transporters.
作者简介
A. Shaheen
Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institutefor Biotechnology and Genetic Engineering (NIBGE); Department of Biochemistry and Biotechnology, University of Gujrat, Hafiz Hayat Campus
Email: moazur.rahman@fulbrightmail.org
巴基斯坦, Faisalabad, 44000; Gujrat, 50700
W. Afridi
Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institutefor Biotechnology and Genetic Engineering (NIBGE)
Email: moazur.rahman@fulbrightmail.org
巴基斯坦, Faisalabad, 44000
S. Mahboob
Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institutefor Biotechnology and Genetic Engineering (NIBGE)
Email: moazur.rahman@fulbrightmail.org
巴基斯坦, Faisalabad, 44000
M. Sana
Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institutefor Biotechnology and Genetic Engineering (NIBGE)
Email: moazur.rahman@fulbrightmail.org
巴基斯坦, Faisalabad, 44000
N. Zeeshan
Department of Biochemistry and Biotechnology, University of Gujrat, Hafiz Hayat Campus
Email: moazur.rahman@fulbrightmail.org
巴基斯坦, Gujrat, 50700
F. Ismat
Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institutefor Biotechnology and Genetic Engineering (NIBGE)
Email: moazur.rahman@fulbrightmail.org
巴基斯坦, Faisalabad, 44000
O. Mirza
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences,University of Copenhagen
Email: moazur.rahman@fulbrightmail.org
丹麦, Copenhagen, 1165
M. Iqbal
Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institutefor Biotechnology and Genetic Engineering (NIBGE)
Email: moazur.rahman@fulbrightmail.org
巴基斯坦, Faisalabad, 44000
M. Rahman
Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institutefor Biotechnology and Genetic Engineering (NIBGE)
编辑信件的主要联系方式.
Email: moazur.rahman@fulbrightmail.org
巴基斯坦, Faisalabad, 44000
补充文件
